RE:RE:RE:New Corp Presentation is up I'm happy to see more anecdotal details and indirect evidence that they are answering some of the hypotheses they postulated about this drug at the start of the program (like it's ability to bypass resistance). But I guess they are most focused on what 1a set out to do and whether it delivered on that. They've shown the drug is relatively stable in blood. They've given us a point where toxicity seems to markedly get worse based on a handful of patients. We have a dose for future patients. And some signs of efficacy. That's the core of what 1a needed to deliver and it seems like it did and they presented the evidence for that and put it in their presentation. I guess all the anecdotal stuff comes up during conversations. I guess we have to accept now that the more solid data on some of the other questions comes as they get deeper into 1b and beyond.
If I'm honest the opportunity in 1a was for them to over-deliver with efficacy. That didn't happen. It seems 1b (especially an extended 1b) should offer a more meaningful shot at that.
It's a bit niche but I'm still fixated on the 8 previous lines of treatment being AVERAGE for their enrolled patients. It still sounds to me very high and the greater opportunity for the drug to be thoroughly tested by maybe a healthier bunch of patients offers some possibilities. I wouldn't mind a question looking at this aspect.
SPCEO1 wrote: They gave us a little new info too. I am not sure why they are not highlighting the fact that the one patient had failed on straight docetaxel but had 53% tumor shrinkage after just three treatments on TH-1902. It is really too bad that patient caught covid and had to discontinue.
qwerty22 wrote: Much clearer.
SPCEO1 wrote:
And it has a little new info on cancer - nothing on phase 1b but some more info on phase 1a regarding side-effects and number of patients treated at different dosage levels.